Therapeutic efficacy of low‐dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases

2018 ◽  
Vol 11 (2) ◽  
pp. O53-O58 ◽  
Author(s):  
Sheng‐Fu Chen ◽  
Hann‐Chorng Kuo
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Overactive Bladder ◽  
Therapeutic Efficacy ◽  
Low Dose ◽  
Nervous System Diseases ◽  
Central Nervous System Diseases ◽  
Overactive Bladder Symptoms ◽  
Bladder Symptoms

Dimephosphone — vasoactive drug for normalization of nervous system function

1993 ◽  
Vol 74 (1) ◽  
pp. 8-12
Author(s):  
R. Kh. Khafizyaiiova ◽  
I. A. Studentsova ◽  
V. I. Danilov ◽  
I. S. Mokrinskaya ◽  
R. A. Garaev ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Experimental Study ◽  
Nervous System ◽  
Cerebral Circulation ◽  
Vasoactive Drug ◽  
System Function ◽  
Nervous System Diseases ◽  
Central Nervous System Diseases ◽  
Clinical Tests ◽  
Nervous System Function

An experimental study of dimephpsphone, using different models of the disorders of cerebrum and cerebral circulation functions, reveals cerebroprotcctive properties and normalizing type of the effect on the regulating mechanisms of cerebral circulation. Clinical tests indicate the efficacy of the drug in different central nervous system diseases in neurological and neurosurgical clinics.

Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases

2020 ◽  
pp. 365-374
Author(s):  
Bernardo F. Sánchez-Dalmau ◽  
Anna Camós-Carreras ◽  
Ruben Torres-Torres ◽  
Johannes Keller ◽  
Laura Sanchez-Vela ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nervous System Diseases ◽  
Central Nervous System Diseases ◽  
Retrograde Degeneration

scholarly journals Low dose intradetrusor injections of onabotulinumtoxinA in women with overactive bladder symptoms or the painful bladder syndrome: unfavorable balance between clinical efficacy and the need for catheterization

2012 ◽  
Vol 26 (1) ◽  
pp. 10
Author(s):  
Jan Groen ◽  
Wouter J.C. Marchand ◽  
Bertil F.M. Blok ◽  
Gert R. Dohle
Keyword(s):  
Overactive Bladder ◽  
Success Rate ◽  
Low Dose ◽  
Painful Bladder Syndrome ◽  
Pressure Flow ◽  
Overactive Bladder Symptoms ◽  
King’S Health Questionnaire ◽  
Painful Bladder ◽  
Pressure Flow Studies ◽  
Bladder Symptoms

We evaluated our results with low dose intradetrusor injections of onabotulinu - mtoxinA in women with overactive bladder symptoms and the painful bladder syndrome in terms of clinically successful outcomes and the need for clean intermittent self-catheterization (CISC) and in relation to urodynamic aspects. The files of patients treated with 100 U of onabotulinumtoxinA injected at 20 sites with sparing of the trigone were retrospectively analyzed. Nearly all patients completed voiding- incontinence diaries and the King’s Health Questionnaire (KHQ) pre- and post-operatively. Cystometric and pressure-flow studies were done in the majority of patients. Success was defined as the patient’s and clinician’s joint choice for re-treatment with the same dose of onabotulinumtoxinA after a period of at least six months of clinical satisfaction. Twenty-six women were treated. On average, the improvement in most voiding diary parameters and in most KHQ categories lasted less than six and three months, respectively. Eight patients (31%) were scheduled for re-treatment with 100 U again after at least six months. No prognostic cystometric parameters were found. Six patients (23%) needed CISC. None of the bladder contraction strength parameters derived from the pressure-flow studies appeared predictive of the need of CISC. We obtained a success rate of 31% after six months with 100 U of onabotulinumtoxinA, while 23% of the patients applied CISC. We consider this success rate low and find the balance between the success rate and the rate of patients needing CISC inadequate.

Sign in / Sign up

Export Citation Format

Share Document